EU Outsources Key Tobacco Control Responsibilities to Third Parties

Feb.27.2023
EU Outsources Key Tobacco Control Responsibilities to Third Parties
The EU outsources tobacco control responsibilities to non-elected bodies, causing concerns over accountability and potential conflicts of interest.

The European Tobacco Harm Reduction Advocates (ETHRA) has stated that the EU has outsourced key responsibilities for tobacco control to unelected organizations. ETHRA coordinates the actions of consumer groups and advocacy organizations throughout Europe. The organization warns that this has raised concerns about accountability and potential conflicts of interest.


EU officials had issued a tender notice for the "Support Action for the Tobacco Control Sector Single Framework Contract" earlier. Recently, they announced that the process has been completed and three contractors have been appointed.


The Spanish research and consultancy firm, Open Evidence, ...


The European Network for Smoking Prevention (ENSP)


Crete University


ETHRA has released a publicly available report which states that as part of their contribution, they will lead an "international consortium". This consortium will include the UK's ICF consultancy company, Brussels-based Milieu legal and policy consultancy, and Vital Strategies funded by Michael Bloomberg.


According to the Consumer Association, the contract will last for four years and is worth 3 million euros (approximately 22.03 million yuan).


According to the statement from ETHRA, the contractor's job will include:


Gather scientific literature, research, or clinical evaluations related to one or more tobacco or nicotine themes.


2. Statistical, market, and measurement analyses related to one or more tobacco or nicotine themes.


Tobacco Control Policy Model,


Behavioral research and analysis of specific issues.


Support for comprehensive health warnings,


Support for tobacco and related product labelling and packaging.


7. Restrictions on ingredients and related content/emission standards.


Support technological investment in information system development.


Conduct a legal assessment for the tobacco control measures of the European Union, countries, and international organizations.


The European Tobacco Harm Reduction Advocates (ETHRA) stated that the introductory notes in the tender specifications of the European Health and Digital Executive Agency (HaDEA) provide the legislative background of the EU's tobacco control policies, with the goal of achieving a "smoke-free tobacco generation" by 2040.


To achieve this goal, the plan is to revise the Tobacco Products Directive, which includes measures such as "implementing plain packaging and banning flavors in a completely transparent manner, improving the evaluation of ingredients through existing EU institutions, expanding taxes to new tobacco products, and addressing tobacco advertising, promotion, and sponsorship on the internet and social media.


According to the author of the document, there are concerns about the regulatory framework of the European Union. Currently, there is no systematic approach to dealing with all new tobacco and emerging products, and there is also a lack of flexibility to address rapidly developing products.


Advocates for reducing the harm of tobacco in Europe say, "This appears to be a daunting task for contractors. More importantly, it signifies that the policy-making responsibilities of the European Commission are now being outsourced to third parties. Accountability issues arise as well: when EU member states receive proposals to amend existing legislation, how do they know which proposals come from responsible officials and what role external actors played in shaping EU legislation?


Another issue is the potential conflict of interest with the winning bidder group. Of course, when it comes to the tobacco industry, they have a responsibility to declare that they have no conflict of interest in the tobacco industry. However, their work may have potential conflicts with other industries, such as the pharmaceutical industry that we may not be aware of.


References:


Efforts to Lobby on Behalf of Tobacco Industry The European Union (EU) has been found to be subcontracting its efforts to control tobacco, potentially undermining efforts to combat smoking. Investigations have discovered that the EU is employing companies which have links to the tobacco industry, leading to allegations of lobbying on behalf of the sector. The subcontractors are tasked with implementing tobacco control policies to be carried out across EU member states. Critics have voiced concern that this conflict of interest could threaten progress in reducing rates of smoking across Europe.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22